In addition to safety concerns about the eye implant, the FDA pointed to deficiencies at the facility where the product is made, Alimera said, adding that the deficiencies would not affect its supply intended for sale in Europe. Simeonidis said a meeting with FDA officials had been "rather unusual" but left the "door open for something good to come out." The FDA said its review panel would convene on Jan. 27 and would assess whether they might identify a patient population whose potential benefits from the device might outweigh the risks. Like many medical device manufacturers, Alimera markets and sells only one product. In the second financial quarter this year, the company reported revenue of $179,000 based on sales of Iluvien, a sustained-release implant used to treat vision problems brought by chronic diabetic macular edema. Alimera's shares fell 23 percent to $2.08, while pSivda shares hit $2.97 on Nasdaq Friday afternoon.